Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effects of Ziltivekimab Versus Placebo on Morbidity and Mortality in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction and Systemic Inflammation

NCT05636176 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.

NCT NCT05636176
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05636176 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effects of Ziltivekimab Versus Placebo on Morbidity and Mortality in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction and Systemic Inflammation
Lead sponsor
Novo Nordisk A/S
Phase
Phase 3
Overall status
Terminated
Start date
May 8, 2023
Completion date
September 3, 2026
Enrollment
4,874 (actual)
Sites
1,013

Conditions

As the registry lists them; a condition with its own page is linked.

heart failure